ערך בספרים למניה: Calidi Bio (CLDI)

Leveraging a science-intensive approach and the expertise of cell biologists, Calidi Biotherapeutics (CLDI) is developing innovative therapies. The change in BVPS reflects the dynamics of net assets, where the 1.49 mark characterizes this parameter. Future prospects depend on clinical trial results and the inflow of investment. Shareholder confidence is supported by stable management establishing partnerships with global medical centers.

From a portfolio management perspective, this indicator determines the portion of equity attributable to a single share after deducting all liabilities, serving as a measure of the business's intrinsic value. By analyzing the absolute level of the book value per share, an investor assesses the financial cushion of Calidi Biotherapeutics (CLDI) for developing its unique stem cell-based virus delivery technology, thereby determining the company's resilience to clinical trial costs.